NCT06234072Not yet recruiting
Comparing Astragalus Plus Gemcitabine to Gemcitabine Alone as Neoadjuvant Treatment for Pancreatic Cancer Patients
Comparison of Neoadjuvant Treatment for Pancreatic Cancer: Astragalus Combined With Gemcitabine Versus Gemcitabine Alone - A Single-Center, Randomized, Double-Blind Study
Shenzhen University General HospitalPhase 2ClinicalTrials.govdrug
Study focus
- Disease/Condition
- Pancreatic Cancer
- Drug/Device/Intervention
- Astragalus + Gemcitabine
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Shenzhen University General Hospital
- Location
- Shenzhen, China
Timeline & enrollment
- Phase
- Phase 2
- Start date
- Feb 01, 2024
- End date
- Jan 01, 2027
- Enrollment
- 120 participants
Primary outcome
Objective response rate (ORR)
Summary
This study compare the efficacy of Astragalus combined with Gemcitabine to Gemcitabine alone
 as neoadjuvant treatment for pancreatic cancer.
ICD-10 classifications
Malignant neoplasm of pancreasMalignant neoplasm: Pancreas, unspecifiedMalignant neoplasm: Head of pancreasMalignant neoplasm: Tail of pancreasMalignant neoplasm: Other parts of pancreas
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06234072
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06234072 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shenzhen University General Hospital and is currently Not yet recruiting. The study focuses on Pancreatic Cancer. Target enrollment is 120 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.